The treatment of children suffering from chronic myelogenous leukemia: A comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation

• Published in: Pediatric transplantation Vol. 17; no. 4; pp. 380 - 386
• Main Authors: Hamidieh, Amir Ali, Ansari, Shahla, Darbandi, Bahram, Soroush, Alborz, Arjmandi Rafsanjani, Khadijeh, Alimoghaddam, Kamran, Bahosh, Gholamreza, Behfar, Maryam, Ghavamzadeh, Ardeshir
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.06.2013
• Subjects: Adolescent; Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Child; children; chronic myeloid leukemia; Cross-Sectional Studies; Female; Follow-Up Studies; hematopoietic stem cell transplantation; Hematopoietic Stem Cell Transplantation - methods; Humans; imatinib; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Male; Piperazines - therapeutic use; Pyrimidines - therapeutic use; Recurrence; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome

HSCT is the only proven treatment option for CML, a rare disease in children. Recently, there are promising reports on the advantageous effect of imatinib mesylate for pediatric patients with CML. We conducted a retrospective study on 33 pediatric patients suffering from CML. Fourteen underwent HSCT...